Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux

References
1 Kelton JG. Heparin-induced thrombocytopenia: an overview. Blood Rev 2002; 16: 77-80.
2 Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 2003; 101: 31-7.
3 Pravinkumar E, Webster NR. HIT/HITT and alternative anticoagulation: current concepts. Br J Anaesth 2003; 90: 676-85.
4 Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121: 535-55.
5 Gallus AS, Coghlan DW. Heparin pentasaccharide. Curr Opin Hematol 2002; 9: 422-9.
6 Petitou M, Herault JP, Bernat A. et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999; 398: 417-22.
7 Keam SJ, Goa KL. Fondaparinux sodium. Drugs 2002; 62: 1673-85.
8 Amiral J, Lormeau JC, Marfaing-Koka A. et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8: 114-7.
9 King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100: 535-40.
10 Wallis DE, Workman DL, Lewis BE. et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106: 629-35.
11 Warkentin TE, Elavathil LJ, Hayward CP. et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 804-12.
12 Arocas V, Bock SC, Raja S. et al. Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding. J Biol Chem 2001; 276: 43809-17.
13 Visentin GP, Moghaddam M, Beery SE. et al. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 2001; 138: 22-31.
14 Savi P, Chong B, Greinacher A. et al. Effect of fondaparinux on platelet activation in the presence of heparin- dependent anti-platelet antibodies. A blinded comparative multicenter study with unfractionated heparin. Blood 2003; 102: 319a.
15 Bauer KA. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm 2001; 58 (Suppl. 02) Suppl S14-S17.
16 Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators. Circulation 2000; 102: 2726-31.
17 Lassen MR, Bauer KA, Eriksson I B. et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-20.
18 Turpie AG, Bauer KA, Eriksson I B, eta l. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-6.
19 Bauer KA, Eriksson I B, Lassen MR. et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolismafter elective major knee surgery. N Engl J Med 2001; 345: 1305-10.
20 Eriksson I B, Bauer KA, Lassen MR. et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolismafter hip-fracture surgery. N Engl J Med 2001; 345: 1298-304.